Enzo Biochem Inc. has concluded its tenure as a publicly traded company following its full acquisition by the private equity firm Battery Ventures. The biotechnology company has been officially delisted from all stock exchanges, with shareholders receiving a final cash payout at the agreed-upon acquisition price.
Shareholders gave their definitive approval for the takeover by a Battery Ventures subsidiary on August 19th. The transaction, which valued the company at approximately $37 million, was finalized on August 28, 2025. Under the terms of the agreement, investors received $0.70 in cash for each share of Enzo Biochem stock they held. This price represented a significant premium to the trading level seen prior to the company’s announcement of a strategic review.
The acquisition marks the end of Enzo Biochem’s long history on public markets. Its shares were immediately delisted and are no longer available for public trading.
Should investors sell immediately? Or is it worth buying Enzo Biochem?
With the transition to private ownership complete, the company is poised for a strategic repositioning under its new leadership. Battery Ventures plans to maintain the company’s focus on its life sciences and research reagents divisions while implementing accelerated innovation and growth initiatives. A leadership change accompanies this new chapter, with Jason Apter appointed as the new Group CEO.
Key Transaction Details:
- Closing Date: The going-private deal was officially completed by Battery Ventures on August 28, 2025.
- Valuation: The transaction was valued at $37 million, with shareholders receiving $0.70 per share.
- Stock Status: The company has been delisted; its shares are no longer tradable.
- New Leadership: Jason Apter has been named the new Group CEO.
- Future Strategy: Focus on accelerating innovation and growth initiatives under private ownership.
This move permanently withdraws Enzo Biochem from the public equity markets, closing a definitive chapter for the company and its investors.
Ad
Enzo Biochem Stock: Buy or Sell?! New Enzo Biochem Analysis from October 17 delivers the answer:
The latest Enzo Biochem figures speak for themselves: Urgent action needed for Enzo Biochem investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from October 17.
Enzo Biochem: Buy or sell? Read more here...
